22-ketocholesterol is an oxysterol, a cholesterol derivative that occurs naturally in the body. It is synthesized in the liver through the oxidation of cholesterol, primarily by the enzyme cholesterol 22-hydroxylase. 22-ketocholesterol has been implicated in a variety of biological processes, including inflammation, cell signaling, and atherosclerosis. It is of particular interest to researchers because it has been shown to have both pro- and anti-inflammatory effects, and its role in cardiovascular disease is complex and not fully understood. 22-ketocholesterol is also a biomarker for cholesterol metabolism and oxidative stress. Research on 22-ketocholesterol focuses on understanding its mechanisms of action, its role in health and disease, and the development of potential therapeutic strategies to modulate its activity.'
```
22-ketocholesterol: RN given refers to (3beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
22-ketocholesterol : A 3beta-sterol that is cholesterol carrying an oxo group at position 22. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 101465 |
| CHEBI ID | 143264 |
| SCHEMBL ID | 4973804 |
| MeSH ID | M0108658 |
| Synonym |
|---|
| nsc-523236 |
| 19243-30-2 |
| 22-ketoc |
| 3beta-hydroxycholest-5-en-22-one |
| 5-cholesten-3beta-ol-22-one |
| 22-ketocholesterol |
| (3beta)-3-hydroxycholest-5-en-22-one |
| CHEBI:143264 |
| 3beta-hydroxy-5-cholestene-22-one |
| (2s)-2-[(3s,8s,9s,10r,13s,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl]-6-methylheptan-3-one |
| (2s)-2-[(3s,8s,9s,10r,13s,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl]-6-methyl-3-heptanone |
| (2s)-2-[(3s,8s,9s,10r,13s,14s,17r)-10,13-dimethyl-3-oxidanyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl]-6-methyl-heptan-3-one |
| A829049 |
| 6ppd342rur , |
| nsc 523236 |
| unii-6ppd342rur |
| cholest-5-en-22-one, 3-hydroxy-, (3beta)- |
| SCHEMBL4973804 |
| 3-hydroxycholest-5-en-22-one # |
| ZJIBAMHOAQWYSE-CNXJXGGASA-N |
| 3-hydroxycholest-5-en-22-one |
| 5-cholesten-3.beta.-ol-22-one |
| cholest-5-en-22-one, 3-hydroxy-, (3.beta.)- |
| 3.beta.-hydroxycholest-5-en-22-one |
| 5-cholesten-3beta- ol-24-one |
| CCA37286 |
| Role | Description |
|---|---|
| EC 1.14.15.6 cholesterol monooxygenase (side-chain-cleaving) inhibitor | Any EC 1.14.15.* (oxidoreductase acting on paired donors, with reduced Fe-S protein as one donor, incorporating 1 O atom) inhibitor that interferes with the action of cholesterol monooxygenase (side-chain-cleaving) (EC 1.14.15.6). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| 3beta-sterol | A sterol in which the hydroxy group at position 3 has beta- configuration. |
| cholestanoid | Any steroid based on a cholestane skeleton and its derivatives. |
| 3beta-hydroxy-Delta(5)-steroid | Any 3beta-hydroxy-steroid that contains a double bond between positions 5 and 6. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (57.14) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.29) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||